List of Excipients in Branded Drug LIPIODOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Guerbet LLC	LIPIODOL	ethiodized oil	67684-1901	POPPY SEED OIL	1969-12-31

Lipiodol Excipient Strategy and Commercial Opportunities in Drug Delivery

Last updated: August 24, 2026

Lipiodol is an iodinated oil with two commercial roles: an FDA-approved radiopaque contrast medium for lymphography and a widely used carrier for transarterial chemoembolization (TACE). Its commercial value comes from radiopacity, vascular retention, and compatibility with selected lipophilic anticancer drugs. The strongest opportunities are not conventional excipient substitution programs. They are regulated combination products, standardized drug-Lipiodol formulations, manufacturing systems, and image-guided delivery platforms.

What is Lipiodol and how does it function in pharmaceutical formulations?

Lipiodol, also called ethiodized oil, is composed of ethyl esters of iodinated fatty acids derived from poppyseed oil. The commercial product contains approximately 480 mg of iodine per mL and is supplied as a sterile injectable oil [1].

In drug delivery, Lipiodol can perform several functions:

Function	Commercial relevance
Radiopaque contrast agent	Allows real-time and post-procedure visualization
Lipophilic drug carrier	Supports delivery of drugs such as doxorubicin in TACE
Vascular-retention medium	Accumulates in selected tumor-feeding arteries, particularly in hepatocellular carcinoma
Formulation phase	Creates an oil phase in water-in-oil or oil-in-water emulsions
Procedure marker	Helps confirm arterial perfusion and embolization distribution

Lipiodol is not a conventional inert excipient such as polyethylene glycol, polysorbate 80, or microcrystalline cellulose. It has pharmacological and diagnostic effects, contains a high iodine load, and can cause clinically significant adverse events. A Lipiodol-based formulation should therefore be evaluated as a combination product or drug-delivery system rather than as a simple excipient change.

What is the FDA regulatory status of Lipiodol?

In the United States, Lipiodol Ultra-Fluid is approved as an iodinated contrast medium for lymphography. Its U.S. labeling does not establish a broad approval for use as a chemotherapy carrier in TACE [1].

FDA-approved and common clinical uses

Use	Regulatory position
Lymphography	FDA-approved indication
Hepatic angiography or tumor localization	Used in clinical practice in selected settings, subject to product labeling and institutional practice
Conventional TACE	Widely used procedure, but the chemotherapy-Lipiodol combination is not equivalent to an FDA-approved fixed-dose combination product
Radioembolization preparation	May be used in procedural workflows, but this is distinct from an approved Lipiodol drug product
Drug-delivery vehicle research	Requires product-specific development and regulatory review

Lipiodol labeling includes warnings involving hypersensitivity, pulmonary or cerebral oil embolization, thyroid effects, and inadvertent vascular administration. These risks materially affect formulation design, dosing, procedural controls, and market access [1].

What excipient strategy is most attractive for Lipiodol?

The highest-value strategy is to position Lipiodol as a controlled delivery phase in a standardized locoregional drug product. The formulation objective is not simply to maximize drug loading. It is to control emulsion stability, droplet size, arterial distribution, tumor retention, drug release, and systemic exposure.

Strategy 1: Standardized Lipiodol-drug emulsions

Conventional TACE often involves physician-prepared mixtures of Lipiodol and a cytotoxic drug. A commercial opportunity exists for a ready-to-use or kit-based formulation with:

• Defined drug concentration
• Controlled oil-to-water ratio
• Validated mixing procedure
• Specified droplet-size distribution
• Defined emulsion stability window
• Reproducible injectability
• Container-closure compatibility
• Standardized preparation time before administration

Doxorubicin is the most commercially established candidate because it is widely used in conventional TACE. Cisplatin, epirubicin, and mitomycin-based combinations have also been used in regional oncology practice, although the regulatory and clinical evidence varies by market [2,3].

A product sponsor could pursue either:

1. A fixed-composition drug-Lipiodol product.
2. A co-packaged kit containing Lipiodol, the anticancer drug, transfer devices, and validated instructions.
3. A formulation technology licensed to hospitals or interventional oncology manufacturers.
4. A platform with multiple cytotoxic payloads and disease-specific protocols.

The kit approach may reduce formulation complexity but still raises compatibility, sterility, stability, and combination-product questions.

Strategy 2: Lipophilic small-molecule delivery

Lipiodol is most commercially attractive for compounds with sufficient lipophilicity or oil-phase affinity. Candidate drugs should be screened for:

• Partition coefficient between Lipiodol and aqueous media
• Chemical stability in iodinated oil
• Solubility at clinically relevant concentrations
• Release kinetics from the emulsion
• Compatibility with mixing and injection
• Local tissue tolerability
• Systemic pharmacokinetics
• Compatibility with embolic agents

Highly hydrophilic drugs may require surfactants, co-solvents, prodrugs, nanoparticles, or ion-pairing technology. Those additions can create new toxicology and regulatory burdens.

Strategy 3: Biodegradable embolic and depot systems

Lipiodol can be combined procedurally with embolic materials, including gelatin-based products. The commercial opportunity is a coordinated system that controls both drug delivery and blood-flow reduction.

Potential product concepts include:

• Lipiodol plus biodegradable microspheres
• Lipiodol plus gelatin sponge particles
• Lipiodol-containing injectable depots
• Radiopaque embolic microspheres
• Image-guided formulations that combine drug delivery and embolization

The key development issue is whether the system improves patient outcomes over established drug-eluting beads or standard TACE while preserving the visualization benefits of Lipiodol.

What formulations are protected by Lipiodol-related intellectual property?

The core Lipiodol composition is based on an old iodinated-oil technology and should not be assumed to provide meaningful new-product exclusivity by itself. Commercial protection is more likely to arise from later claims covering:

• Specific drug-to-Lipiodol ratios
• Stable emulsion compositions
• Surfactant systems
• Droplet-size ranges
• Mixing and administration devices
• Drug-loading processes
• Sustained-release formulations
• Combination use with embolic materials
• Disease-specific TACE protocols
• Imaging-guided dosing methods
• Manufacturing and purification processes

Formulation patent strategy

A robust patent program would separate claims into several families:

Patent family	Example claim focus
Composition	Lipiodol, drug, surfactant, co-solvent, stabilizer
Physical properties	Droplet size, viscosity, phase ratio, density
Manufacturing	Order of addition, mixing energy, temperature, filtration
Administration	Catheter, syringe, transfer device, injection sequence
Therapeutic use	HCC, colorectal liver metastases, cholangiocarcinoma
Imaging	Radiopacity threshold or image-guided dose selection
Combination therapy	Lipiodol with embolic agents or systemic therapy

Patents directed only to the use of Lipiodol with a known cytotoxic may face validity and obviousness pressure. Stronger claims would connect formulation parameters to measured performance, such as improved tumor retention, reduced systemic exposure, reduced catheter occlusion, or more consistent intratumoral distribution.

How strong is the Lipiodol patent estate?

The core product estate is likely weak as a composition-of-matter barrier because ethiodized oil has been used for decades. The stronger barriers are commercial and regulatory:

Protection type	Expected strength
Core ethiodized-oil composition	Low, because of product age and historical use
Trademark and brand recognition	Moderate to strong in interventional radiology
Manufacturing know-how	Moderate, particularly for iodine content, purification, sterility, and consistency
Specific drug-Lipiodol formulations	Potentially strong if supported by reproducible performance data
Delivery devices and kits	Moderate to strong where device claims are differentiated
Clinical protocols	Variable and vulnerable to design-around
Regulatory approval	Stronger than a simple formulation patent for a validated combination product
Physician-prepared mixtures	Limited exclusivity and substantial variability

The principal strategic error would be treating Lipiodol itself as the moat. The defensible asset is a validated delivery system with clinical evidence, procedural standardization, and regulatory clearance.

What Orange Book status does Lipiodol have?

Lipiodol is an FDA-approved prescription drug and should be reviewed in the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database for NDA, patent, exclusivity, and generic-competition information [4].

The public prescribing information identifies the product and its approved lymphography indication but does not create a broad patent barrier for every off-label Lipiodol-based TACE use [1]. A sponsor developing a new Lipiodol-drug product would generally need to establish its own product-specific regulatory and intellectual-property position.

Because Lipiodol is an injectable oil with specialized manufacturing and limited market size, generic competition may be constrained by technical barriers even where composition patents are absent. Those barriers include:

• Sterile oil manufacturing
• Consistent iodine content
• Control of impurities and residual solvents
• Container compatibility
• Injectable viscosity
• Global sourcing of iodinated fatty-acid raw materials
• Limited commercial scale
• Hospital and distributor purchasing relationships

When does Lipiodol lose exclusivity?

Lipiodol’s underlying technology is old, and the principal commercial question is not a single future patent-expiration date. The relevant issue is whether a later patent, regulatory exclusivity period, or manufacturing right covers a specific product or use.

Exclusivity timeline

Asset	Likely exclusivity driver
Historical ethiodized-oil technology	Core rights generally expected to be expired
Current branded Lipiodol product	Trademark, manufacturing capability, regulatory approval, and supply position
New drug-Lipiodol combination	New patents, clinical data, formulation claims, and product-specific approval
Ready-to-use kit	Combination-product patents, device claims, and regulatory exclusivity
New therapeutic indication	Method-of-use patents and clinical exclusivity, where available
Biosimilar exclusivity	Not applicable to Lipiodol

There is no biosimilar pathway for Lipiodol because it is a chemically defined iodinated oil rather than a biological product. Competition would arise through generic, hybrid, 505(b)(2), device, or combination-product pathways rather than biosimilar approval.

Which companies compete with Lipiodol-based delivery?

Competition exists at the procedure and delivery-platform level.

Primary competitive categories

Category	Representative products or technologies	Competitive advantage
Lipiodol-based conventional TACE	Lipiodol plus doxorubicin or other cytotoxics	Low equipment burden, radiopacity, procedural familiarity
Drug-eluting beads	Doxorubicin-loaded microspheres	More standardized drug loading and sustained release
Bland embolization	Microspheres or particles without chemotherapy	Simpler procedure and lower drug-related toxicity
Y-90 radioembolization	Radioactive microspheres	Radiation-based treatment and different patient-selection model
Ablation	Microwave or radiofrequency ablation	Local treatment without arterial embolization
Systemic therapy	Immunotherapy and targeted agents	Noninvasive treatment and broader disease coverage
Image-guided combination therapy	TACE combined with systemic therapy or ablation	Potentially expanded treatment efficacy

Drug-eluting beads are the closest direct formulation competitor. Their advantage is manufacturing control over drug loading and release. Lipiodol-based TACE retains value where radiographic visibility, operator familiarity, cost, and procedural flexibility are important.

What licensing deals could be built around Lipiodol?

A Lipiodol commercialization program could support several deal structures:

Platform licensing

A formulation company licenses a proprietary emulsion or drug-loading process to the Lipiodol manufacturer or an oncology company. Consideration could include upfront payments, development milestones, royalties, and territory-specific rights.

Co-development with an oncology sponsor

An interventional oncology company partners with a doxorubicin, cisplatin, or novel liver-cancer drug developer. The parties share clinical development costs and define rights to the combination product.

Hospital procedure-kit partnership

A manufacturer supplies a standardized kit to hospitals, including Lipiodol, drug preparation components, transfer devices, and procedural instructions. The commercial model may rely on supply contracts rather than traditional drug royalties.

Device-drug combination partnership

A catheter or embolic-device company integrates Lipiodol delivery into a controlled administration system. This model could create stronger differentiation than a formulation-only product.

Regional distribution licensing

Because interventional oncology practice differs significantly by country, regional licensing may be appropriate for Europe, North America, China, Japan, Latin America, and the Middle East. Local regulatory classification and procurement channels will determine the economics.

What manufacturing and intellectual-property barriers affect Lipiodol products?

Manufacturing is a meaningful competitive barrier. The product requires controlled iodination of fatty-acid esters, removal of reactive impurities, sterilization or aseptic processing, and consistent iodine concentration.

Key CMC challenges

• Batch-to-batch iodine-content control
• Fatty-acid composition consistency
• Oxidative stability
• Sterility assurance
• Endotoxin control
• Extractables and leachables from syringes and vials
• Stability of drug-loaded emulsions
• Phase separation during storage
• Catheter injectability
• Compatibility with embolic materials
• Control of oil embolization risk

A formulation sponsor should generate comparative data on viscosity, particle or droplet distribution, drug release, radiopacity, and tissue retention. These data can support both regulatory submissions and patent claims.

What regulatory pathway applies to a new Lipiodol-drug product?

The pathway depends on the product’s intended claims and composition.

Potential regulatory routes

Product concept	Likely regulatory issue
New Lipiodol formulation with the same indication	NDA supplement or new drug application analysis
Lipiodol plus approved chemotherapy	Combination product and clinical-bridging requirements
New drug delivered with Lipiodol	Full drug development program may be required
Lipiodol plus embolic device	Drug-device combination-product classification
Ready-to-use kit	Container, sterility, compatibility, labeling, and combination-product review
New TACE indication	Clinical evidence for the specific disease and treatment protocol

A sponsor cannot assume that historical physician preparation creates an abbreviated approval route. A commercially supplied product with defined composition, manufacturing controls, and therapeutic claims will be judged on its own regulatory profile.

What litigation and Paragraph IV risks affect Lipiodol?

There is no established biosimilar litigation pathway, and the core ethiodized-oil technology is too old to support a conventional new-product exclusivity strategy. Litigation risk would more likely arise from:

• Patents on a specific Lipiodol-drug emulsion
• Device patents covering preparation or injection
• Method-of-use patents for TACE
• Trademark disputes involving the Lipiodol name
• Product liability claims involving embolization or off-label chemotherapy mixtures
• Contract disputes over exclusive supply or distribution
• ANDA or 505(b)(2) challenges to later-listed patents

A Paragraph IV challenge would matter only if a relevant listed patent covered an approved drug product and remained enforceable. For new combination formulations, litigation risk would depend on the sponsor’s own patents and the claims of competing products. The absence of a strong core composition patent means freedom-to-operate analysis should focus on formulation, device, and method-of-use claims.

What revenue exposure and commercial opportunities exist?

Lipiodol-based products are most attractive in markets with high volumes of interventional oncology procedures, established TACE infrastructure, and reimbursement for locoregional liver-cancer treatment.

Commercial opportunity segments

Segment	Opportunity
Standardized doxorubicin-Lipiodol kits	Replaces variable hospital compounding
Novel lipophilic oncology drugs	Uses Lipiodol as a local-delivery platform
Radiopaque embolic systems	Combines visualization with controlled embolization
Procedure-specific devices	Improves preparation and injection reproducibility
Contract manufacturing	Supplies validated emulsions or kits to regional partners
Companion imaging tools	Links Lipiodol distribution to treatment planning
Clinical decision software	Uses Lipiodol retention and imaging to guide retreatment
Emerging-market access	Lower-cost alternatives to complex bead-based systems

Revenue risk is concentrated in procedure volume, hospital purchasing, clinical guideline adoption, reimbursement, and supply continuity. A successful product would need to demonstrate more than radiopacity. It would need to reduce procedure variability, improve outcomes, lower total treatment cost, or simplify preparation.

How does Lipiodol compare with drug-eluting beads?

Attribute	Lipiodol-based TACE	Drug-eluting beads
Drug loading	Usually prepared at the treatment site	Manufactured or loaded under controlled conditions
Radiopacity	Strong	Depends on bead technology
Release control	Highly dependent on emulsion and procedure	More standardized
Physician flexibility	High	Lower once bead product is selected
Manufacturing complexity	Lower for procedural mixtures, higher for commercial kits	High but standardized
Patent opportunity	Formulation, device, method, kit	Bead composition, loading, release, device
Regulatory reproducibility	Challenging for hospital-prepared mixtures	Stronger for defined commercial products
Main weakness	Variability and systemic leakage	Cost, delivery limitations, and product rigidity

Lipiodol’s strongest competitive position is as a flexible and visible carrier. Its weakest position is lack of standardization. Commercial development should focus on closing that standardization gap.

Key Takeaways

• Lipiodol is ethiodized oil, not a conventional inert excipient.
• Its commercial value is based on radiopacity, lipophilicity, and vascular retention.
• The strongest opportunity is a standardized Lipiodol-drug formulation or procedure kit.
• Doxorubicin-based TACE is the most established development target.
• Core composition protection is likely weak because the technology is old.
• New protection should focus on emulsions, drug loading, devices, dosing methods, and clinical use.
• Lipiodol has no biosimilar pathway.
• Drug-eluting beads are the principal formulation-level competitor.
• Manufacturing consistency and procedural reproducibility are major barriers to entry.
• A new Lipiodol-drug product would require product-specific regulatory analysis rather than reliance on historical off-label use.

FAQs

Can Lipiodol be used as an excipient in an oral drug product?

No. Lipiodol is an injectable iodinated oil with a specialized radiopaque and vascular-delivery profile. Its development is more relevant to injectable, locoregional, and image-guided products than to oral formulations.

Is Lipiodol approved for chemotherapy delivery in the United States?

The FDA-approved labeling covers lymphography. Lipiodol-based chemotherapy delivery in TACE is a clinical procedure and does not automatically establish approval of a fixed Lipiodol-chemotherapy combination [1].

Can a company patent a doxorubicin-Lipiodol emulsion?

Potentially, but patent strength would depend on novelty, nonobviousness, claim specificity, and supporting performance data. Broad claims covering only the known combination would face greater validity risk than claims directed to defined formulation parameters or demonstrated clinical advantages.

Is Lipiodol a drug, device, or excipient?

The commercial product is an injectable drug and contrast medium. In a drug-delivery system, it may function as a carrier phase, but its biological and diagnostic effects prevent it from being treated as a purely inert excipient.

What is the best commercial model for a Lipiodol formulation company?

A standardized drug-Lipiodol kit or drug-device combination is generally more defensible than selling an unprotected formulation concept. The business case improves when the product reduces hospital compounding, improves dose reproducibility, and has a defined regulatory pathway.

References

1. U.S. Food and Drug Administration. (2022). Lipiodol Ultra-Fluid prescribing information. Guerbet LLC.

2. Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. F. H. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 64(1), 106-116.

3. European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182-236.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.